Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420132 · ClinicalTrials.gov registry record
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 47
- Enrollment target
NCT02420132 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 47 participants.
The verdict
NCT02420132 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab therapy. In the main, decentralized study, participants will be recruited via digital media, advocacy groups, or through their own ophthalmologist. The traditional substudy will evaluate the association between visual acuity and anatomical markers of disease status determined using clinical "gold standard" assessments (certified Early Treatment Diabetic Retinopathy Study \[ETDRS\] protocol visual acuity and macula optical coherence tomography \[OCT\]) and the results of home vision testing using the myVisionTrack\^TM (mVT) application.
Interventions
- OTHER Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-04-20 |
| Est. Completion | 2016-08-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420132
The ClinicalTrials.gov registry entry for NCT02420132 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT02420132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420132 about?
NCT02420132 is a clinical study titled "Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)". This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab therapy. In the main, decentralized study, participants will be recruited...
What is the current status of trial NCT02420132?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2015-04-20. Estimated completion is 2016-08-25.
What interventions are being tested in trial NCT02420132?
The interventions under investigation include: Ranibizumab (OTHER).
Who is sponsoring clinical trial NCT02420132?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.